Literature DB >> 21448138

Heart failure: pentraxin 3—a marker of diastolic dysfunction and HF?

Bernhard M Kaess, Ramachandran S Vasan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21448138      PMCID： PMC3236065          DOI： 10.1038/nrcardio.2011.50

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  10 in total

Review 1.  Pentraxins: multifunctional proteins at the interface of innate immunity and inflammation.

Authors:  Livija Deban; Barbara Bottazzi; Cecilia Garlanda; Yeny Martinez de la Torre; Alberto Mantovani
Journal:  Biofactors       Date:  2009 Mar-Apr       Impact factor: 6.113

2.  PTX3 expression in the heart tissues of patients with myocardial infarction and infectious myocarditis.

Authors:  Manuela Nebuloni; Fabio Pasqualini; Pietro Zerbi; Eleonora Lauri; Alberto Mantovani; Luca Vago; Cecilia Garlanda
Journal:  Cardiovasc Pathol       Date:  2010-03-30       Impact factor: 2.185

Review 3.  Biomarkers in heart failure.

Authors:  Eugene Braunwald
Journal:  N Engl J Med       Date:  2008-05-15       Impact factor: 91.245

Review 4.  Epidemiology of diastolic heart failure.

Authors:  Theophilius E Owan; Margaret M Redfield
Journal:  Prog Cardiovasc Dis       Date:  2005 Mar-Apr       Impact factor: 8.194

5.  Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response.

Authors:  Cecilia Garlanda; Emilio Hirsch; Silvia Bozza; Antonietta Salustri; Marika De Acetis; Rachele Nota; Alessia Maccagno; Federica Riva; Barbara Bottazzi; Giuseppe Peri; Andrea Doni; Luca Vago; Marina Botto; Rita De Santis; Paolo Carminati; Gregorio Siracusa; Fiorella Altruda; Annunciata Vecchi; Luigina Romani; Alberto Mantovani
Journal:  Nature       Date:  2002-11-14       Impact factor: 49.962

6.  Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction.

Authors:  Junichi Matsubara; Seigo Sugiyama; Toshimitsu Nozaki; Koichi Sugamura; Masaaki Konishi; Keisuke Ohba; Yasushi Matsuzawa; Eiichi Akiyama; Eiichiro Yamamoto; Kenji Sakamoto; Yasuhiro Nagayoshi; Koichi Kaikita; Hitoshi Sumida; Shokei Kim-Mitsuyama; Hisao Ogawa
Journal:  J Am Coll Cardiol       Date:  2011-02-15       Impact factor: 24.094

7.  Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis.

Authors:  Giuseppe Danilo Norata; Patrizia Marchesi; Vivek Krishna Pulakazhi Venu; Fabio Pasqualini; Achille Anselmo; Federica Moalli; Irene Pizzitola; Cecilia Garlanda; Alberto Mantovani; Alberico Luigi Catapano
Journal:  Circulation       Date:  2009-08-10       Impact factor: 29.690

8.  C-reactive protein in heart failure: prognostic value and the effect of valsartan.

Authors:  Inder S Anand; Roberto Latini; Viorel G Florea; Michael A Kuskowski; Thomas Rector; Serge Masson; Stefano Signorini; Paolo Mocarelli; Allen Hester; Robert Glazer; Jay N Cohn
Journal:  Circulation       Date:  2005-08-29       Impact factor: 29.690

9.  Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study.

Authors:  Ramachandran S Vasan; Lisa M Sullivan; Ronenn Roubenoff; Charles A Dinarello; Tamara Harris; Emelia J Benjamin; Douglas B Sawyer; Daniel Levy; Peter W F Wilson; Ralph B D'Agostino
Journal:  Circulation       Date:  2003-03-25       Impact factor: 29.690

Review 10.  Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3.

Authors:  Alberto Mantovani; Cecilia Garlanda; Andrea Doni; Barbara Bottazzi
Journal:  J Clin Immunol       Date:  2007-09-09       Impact factor: 8.317
  10 in total
  9 in total

1.  The Utility of Pentraxin and Modified Prognostic Scales in Predicting Outcomes of Patients with End-Stage Heart Failure.

Authors:  Wioletta Szczurek-Wasilewicz; Michał Skrzypek; Ewa Romuk; Mariusz Gąsior; Bożena Szyguła-Jurkiewicz
Journal:  J Clin Med       Date:  2022-05-04       Impact factor: 4.964

2.  Shenfu Injection suppresses inflammation by targeting haptoglobin and pentraxin 3 in rats with chronic ischemic heart failure.

Authors:  Si-Dao Zheng; Hong-Jin Wu; Shao-Ping Yu; Jian-Xun Ren; Wei-Wei Duo; Zeng-Chun Ma; Yue Gao; Sheng-Qi Wang; Yu-Na Liu
Journal:  Chin J Integr Med       Date:  2013-03-15       Impact factor: 1.978

3.  The acute-phase protein PTX3 is an essential mediator of glial scar formation and resolution of brain edema after ischemic injury.

Authors:  Beatriz Rodriguez-Grande; Matimba Swana; Loan Nguyen; Pavlos Englezou; Samaneh Maysami; Stuart M Allan; Nancy J Rothwell; Cecilia Garlanda; Adam Denes; Emmanuel Pinteaux
Journal:  J Cereb Blood Flow Metab       Date:  2013-12-18       Impact factor: 6.200

4.  Long pentraxin PTX3 is upregulated systemically and centrally after experimental neurotrauma, but its depletion leaves unaltered sensorimotor deficits or histopathology.

Authors:  Marco Oggioni; Domenico Mercurio; Denise Minuta; Stefano Fumagalli; Katarzyna Popiolek-Barczyk; Marina Sironi; Agata Ciechanowska; Stefania Ippati; Daiana De Blasio; Carlo Perego; Joanna Mika; Cecilia Garlanda; Maria-Grazia De Simoni
Journal:  Sci Rep       Date:  2021-05-05       Impact factor: 4.379

5.  Pentraxin-3 as a marker of advanced atherosclerosis results from the Bruneck, ARMY and ARFY Studies.

Authors:  Michael Knoflach; Stefan Kiechl; Alberto Mantovani; Ivan Cuccovillo; Barbara Bottazzi; Qingbo Xu; Qingzhong Xiao; Arno Gasperi; Agnes Mayr; Marlene Kehrer; Johann Willeit; Georg Wick
Journal:  PLoS One       Date:  2012-02-03       Impact factor: 3.240

6.  Pentraxin 3 mediates neurogenesis and angiogenesis after cerebral ischaemia.

Authors:  Beatriz Rodriguez-Grande; Lidiya Varghese; Francisco Molina-Holgado; Olivera Rajkovic; Cecilia Garlanda; Adam Denes; Emmanuel Pinteaux
Journal:  J Neuroinflammation       Date:  2015-01-24       Impact factor: 8.322

7.  Follistatin like 1 Regulates Hypertrophy in Heart Failure with Preserved Ejection Fraction.

Authors:  Komei Tanaka; María Valero-Muñoz; Richard M Wilson; Eric E Essick; Conor T Fowler; Kazuto Nakamura; Maurice van den Hoff; Noriyuki Ouchi; Flora Sam
Journal:  JACC Basic Transl Sci       Date:  2016-06-27

Review 8.  Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases.

Authors:  Fabrizia Bonacina; Andrea Baragetti; Alberico Luigi Catapano; Giuseppe Danilo Norata
Journal:  Mediators Inflamm       Date:  2013-04-07       Impact factor: 4.711

9.  Sex-specific microRNAs in women with diabetes and left ventricular diastolic dysfunction or HFpEF associate with microvascular injury.

Authors:  Barend W Florijn; Gideon B Valstar; Jacques M G J Duijs; Roxana Menken; Maarten J Cramer; Arco J Teske; Chahinda Ghossein-Doha; Frans H Rutten; Marc E A Spaanderman; Hester M den Ruijter; Roel Bijkerk; Anton Jan van Zonneveld
Journal:  Sci Rep       Date:  2020-08-18       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.